Immunovia AB (publ) reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was SEK 0.155 million compared to SEK 0.502 million a year ago. Revenue was SEK 0.21 million compared to SEK 0.513 million a year ago.

Net loss was SEK 49.02 million compared to SEK 67.32 million a year ago. Basic loss per share from continuing operations was SEK 1.08 compared to SEK 2.97 a year ago. Diluted loss per share from continuing operations was SEK 1.08 compared to SEK 2.97 a year ago.